DE873543C
(en)
|
1942-10-28 |
1953-04-16 |
Basf Ag |
Process for the production of dicarbamic acid esters containing hydroxyl or sulfhydryl groups
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
US4550163A
(en)
|
1979-02-05 |
1985-10-29 |
Abbott Laboratories |
Ligand analog-irreversible enzyme inhibitor conjugates
|
US20030232355A1
(en)
|
1992-05-22 |
2003-12-18 |
Isis Pharmaceuticals, Inc. |
Double-stranded peptide nucleic acids
|
US5631148A
(en)
|
1994-04-22 |
1997-05-20 |
Chiron Corporation |
Ribozymes with product ejection by strand displacement
|
GB9621367D0
(en)
|
1996-10-14 |
1996-12-04 |
Isis Innovation |
Chiral peptide nucleic acids
|
US6197557B1
(en)
|
1997-03-05 |
2001-03-06 |
The Regents Of The University Of Michigan |
Compositions and methods for analysis of nucleic acids
|
EP1013770A1
(en)
|
1998-12-23 |
2000-06-28 |
Université Louis Pasteur de Strasbourg |
Non-viral transfection vector
|
FR2790757B1
(en)
|
1999-03-09 |
2003-08-01 |
Bioalliance Pharma |
OLIGONUCLEOTIDES CONTAINING AN ANTI-SENSE SEQUENCE STABILIZED BY A SECONDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
|
US6852334B1
(en)
|
1999-04-20 |
2005-02-08 |
The University Of British Columbia |
Cationic peg-lipids and methods of use
|
US7833992B2
(en)
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
US6962906B2
(en)
|
2000-03-14 |
2005-11-08 |
Active Motif |
Oligonucleotide analogues, methods of synthesis and methods of use
|
CA2439750A1
(en)
|
2001-03-09 |
2002-09-19 |
Boston Probes, Inc. |
Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation
|
AU2004266311B2
(en)
|
2001-05-18 |
2009-07-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US6905827B2
(en)
|
2001-06-08 |
2005-06-14 |
Expression Diagnostics, Inc. |
Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
|
CA2465129A1
(en)
|
2001-10-29 |
2003-05-08 |
Mcgill University |
Acyclic linker-containing oligonucleotides and uses thereof
|
US20060111312A1
(en)
|
2002-02-22 |
2006-05-25 |
The John Hopkins University |
Antigene locks and therapeutic uses thereof
|
US20040248296A1
(en)
|
2002-03-20 |
2004-12-09 |
Beresford Paul J. |
HIV therapeutic
|
EP1857547B2
(en)
|
2002-08-05 |
2020-12-02 |
Silence Therapeutics GmbH |
Further novel forms of interfering RNA molecules
|
AU2003256857A1
(en)
|
2002-08-08 |
2004-02-25 |
Dharmacon, Inc. |
Short interfering rnas having a hairpin structure containing a non-nucleotide loop
|
US6936651B2
(en)
|
2002-12-17 |
2005-08-30 |
E. I. Du Pont De Nemours And Company |
Compatibility improvement in crystalline thermoplastics with mineral fillers
|
WO2004090108A2
(en)
|
2003-04-03 |
2004-10-21 |
Alnylam Pharmaceuticals |
Irna conjugates
|
US20050053979A1
(en)
|
2003-06-12 |
2005-03-10 |
Livak Kenneth J. |
Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same
|
US8106180B2
(en)
|
2003-08-07 |
2012-01-31 |
Whitehead Institute For Biomedical Research |
Methods and products for expression of micro RNAs
|
WO2005030960A1
(en)
|
2003-09-30 |
2005-04-07 |
Anges Mg, Inc. |
Staple type oligonucleotide and drug comprising the same
|
JP2007508030A
(en)
|
2003-10-14 |
2007-04-05 |
カーネル・バイオファーマ・インコーポレイテッド |
Two-phase PNA conjugate for delivering PNA across the blood brain barrier
|
WO2005037317A2
(en)
|
2003-10-17 |
2005-04-28 |
Cornell Research Foundation, Inc. |
Mast cell-derived renin
|
US7615618B2
(en)
|
2004-06-30 |
2009-11-10 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a non-phosphate backbone linkage
|
EP2298892A3
(en)
|
2004-08-23 |
2011-11-16 |
Sylentis S.A.U. |
Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
|
WO2006022325A1
(en)
|
2004-08-26 |
2006-03-02 |
Nippon Shinyaku Co., Ltd. |
Galactose derivative, drug carrier and medicinal composition
|
EP1789551A2
(en)
|
2004-08-31 |
2007-05-30 |
Sylentis S.A.U. |
Methods and compositions to inhibit p2x7 receptor expression
|
WO2006044322A2
(en)
|
2004-10-12 |
2006-04-27 |
The Rockefeller University |
Micrornas
|
DK2302055T3
(en)
|
2004-11-12 |
2014-10-13 |
Asuragen Inc |
Methods and compositions involving miRNA and miRNA inhibitor molecules
|
EP1838875A4
(en)
|
2004-12-30 |
2010-08-25 |
Todd M Hauser |
Compositions and methods for modulating gene expression using self-protected oligonucleotides
|
DE602007004463D1
(en)
|
2006-03-01 |
2010-03-11 |
Nippon Shinyaku Co Ltd |
GALACTOSEDERIVATE, MEDICAMENT AND MEDICAL COMPOSITION
|
EP2023939B1
(en)
|
2006-05-05 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of pcsk9
|
NZ572666A
(en)
*
|
2006-05-11 |
2010-11-26 |
Alnylam Pharmaceuticals Inc |
Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene
|
EP2700638A1
(en)
|
2006-05-31 |
2014-02-26 |
The Regents Of the University of California |
Purine analogs
|
EP1890152A1
(en)
|
2006-08-14 |
2008-02-20 |
Charite Universitätsmedizin-Berlin |
Determination of renin/prorenin receptor activity
|
JP2008220366A
(en)
|
2007-02-16 |
2008-09-25 |
National Institute Of Advanced Industrial & Technology |
Modification type pna/rna complex
|
JP5145557B2
(en)
|
2007-03-01 |
2013-02-20 |
財団法人ヒューマンサイエンス振興財団 |
Tumor growth inhibitor containing microRNA as active ingredient, and pharmaceutical composition for cancer treatment
|
BRPI0809130A2
(en)
|
2007-03-21 |
2014-08-26 |
Brookhaven Science Ass Llc |
HAIRPIN-ANTISENSE COMBINED COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION
|
CN101121934B
(en)
|
2007-04-11 |
2011-12-07 |
哈尔滨医科大学 |
Multiple target points miRNA antisense nucleic acid technique
|
WO2008137867A2
(en)
|
2007-05-03 |
2008-11-13 |
Rosetta Inpharmatics Llc |
Compositions comprising mir34 therapeutic agents for treating cancer
|
JP5296328B2
(en)
|
2007-05-09 |
2013-09-25 |
独立行政法人理化学研究所 |
Single-stranded circular RNA and method for producing the same
|
US20090123501A1
(en)
|
2007-05-17 |
2009-05-14 |
Baylor College Of Medicine |
Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
|
EP2155911B1
(en)
|
2007-05-23 |
2013-08-28 |
Dharmacon, Inc. |
Micro-RNA scaffolds, non-naturally occurring micro-RNAs, and methods for optimizing non-naturally occurring micro-RNAs
|
WO2008150897A2
(en)
|
2007-05-31 |
2008-12-11 |
University Of Iowa Research Foundation |
Reduction of off-target rna interference toxicity
|
US20110212075A1
(en)
|
2007-06-25 |
2011-09-01 |
Siemens Aktiengesellschaft |
Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders
|
EP2193140B1
(en)
*
|
2007-08-27 |
2016-11-02 |
1Globe Health Institute LLC |
Compositions of asymmetric interfering rna and uses thereof
|
US8283331B2
(en)
|
2007-10-09 |
2012-10-09 |
Children's Medical Center Corporation |
Methods to regulate miRNA processing by targeting Lin-28
|
AU2008309520A1
(en)
|
2007-10-12 |
2009-04-16 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin |
Method for opening tight junctions
|
TW200927177A
(en)
|
2007-10-24 |
2009-07-01 |
Nat Inst Of Advanced Ind Scien |
Lipid-modified double-stranded RNA having potent RNA interference effect
|
AR069328A1
(en)
|
2007-11-15 |
2010-01-13 |
Alcon Mfg Ltd |
RELEASE OF SHORT OR SIRNA INTERFERENT RNA, INTERMEDIATED BY LOW DENSITY LIPOPROTEIN RECEPTOR
|
US20100317714A1
(en)
|
2007-11-29 |
2010-12-16 |
Suzhou Ribo Life Science Co., Ltd |
Complex molecule interfering the expression of target genes and its preparing methods
|
EP4074344A1
(en)
|
2007-12-04 |
2022-10-19 |
Arbutus Biopharma Corporation |
Targeting lipids
|
WO2009076321A2
(en)
|
2007-12-07 |
2009-06-18 |
Halo-Bio Rnai Therapeutics Inc. |
Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
|
US20110055965A1
(en)
|
2008-02-15 |
2011-03-03 |
Hiroshi Abe |
Cycle single-stranded nucleic acid complex and method for producing the same
|
CN101981185B
(en)
|
2008-03-31 |
2013-07-10 |
独立行政法人产业技术综合研究所 |
Double-stranded lipid-modified RNA having high RNA interference effect
|
WO2009126563A1
(en)
|
2008-04-11 |
2009-10-15 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for the regulation of microrna processing
|
WO2009143619A1
(en)
|
2008-05-27 |
2009-12-03 |
Chum |
Methods of treating or preventing obesity and obesity-related hypertension
|
WO2010056737A2
(en)
|
2008-11-11 |
2010-05-20 |
Mirna Therapeutics, Inc. |
Methods and compositions involving mirnas in cancer stem cells
|
WO2010058824A1
(en)
|
2008-11-19 |
2010-05-27 |
国立大学法人岐阜大学 |
Substance for regulating differentiation into mesenchymal cell, and use thereof
|
JP2012521766A
(en)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
RNA interference-mediated inhibition of high affinity IgE receptor α chain (FCεR1α) gene expression using small interfering nucleic acids (siNA)
|
US9200276B2
(en)
|
2009-06-01 |
2015-12-01 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotides for multivalent RNA interference, compositions and methods of use thereof
|
EP2454371B1
(en)
|
2009-07-13 |
2021-01-20 |
Somagenics, Inc. |
Chemical modification of small hairpin rnas for inhibition of gene expression
|
WO2011009624A1
(en)
|
2009-07-22 |
2011-01-27 |
Cenix Bioscience Gmbh |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
WO2011028550A1
(en)
|
2009-08-24 |
2011-03-10 |
Merck Sharp & Dohme Corp. |
Segmented micro rna mimetics
|
US20110052666A1
(en)
|
2009-09-03 |
2011-03-03 |
Medtronic, Inc. |
Compositions, Methods, and Systems for SIRNA Delivery
|
JP2012503494A
(en)
|
2009-11-06 |
2012-02-09 |
チュン−アン ユニバーシティ インダストリー−アカデミー コーオペレイション ファンデイション |
Gene carriers containing nanoparticles
|
ES2749426T3
(en)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Nucleic Acid Administration Methods and Compositions
|
EP2516010A2
(en)
|
2009-12-23 |
2012-10-31 |
Novartis AG |
Lipids, lipid compositions, and methods of using them
|
CA2784547A1
(en)
|
2009-12-23 |
2011-06-30 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
Influenza targets
|
JP6060071B2
(en)
|
2010-03-24 |
2017-01-11 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
RNA interference in skin and fibrosis applications
|
CN101845071B
(en)
|
2010-03-25 |
2012-02-01 |
北京欧凯纳斯科技有限公司 |
Nucleoside derivative of 2' or 3' coupling amino acid, preparation method and application thereof
|
JP5555940B2
(en)
|
2010-04-14 |
2014-07-23 |
国立大学法人佐賀大学 |
Method for detecting proliferative diabetic retinopathy and screening method for prophylactic / therapeutic agent
|
JP5892608B2
(en)
|
2010-04-19 |
2016-03-23 |
国立研究開発法人理化学研究所 |
Stabilization of functional nucleic acids
|
SI2561078T1
(en)
|
2010-04-23 |
2019-01-31 |
Cold Spring Harbor Laboratory |
NOVEL STRUCTURALLY DESIGNED shRNAs
|
HUE037500T2
(en)
|
2010-07-08 |
2018-08-28 |
Bonac Corp |
Single-strand nucleic acid molecule for controlling gene expression
|
US8785121B2
(en)
|
2010-07-08 |
2014-07-22 |
Bonac Corporation |
Single-stranded nucleic acid molecule for controlling gene expression
|
WO2012012676A2
(en)
|
2010-07-22 |
2012-01-26 |
The University Of North Carolina At Chapel Hill |
Use of mir-29 for cell protection
|
EP2639307B1
(en)
*
|
2010-08-03 |
2015-03-04 |
Bonac Corporation |
Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
|
US8691782B2
(en)
|
2010-08-03 |
2014-04-08 |
Bonac Corporation |
Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
|
EP3406730B1
(en)
|
2010-08-31 |
2022-02-23 |
Sirna Therapeutics, Inc. |
Novel single chemical entities and methods for delivery of oligonucleotides
|
RU2013129999A
(en)
|
2010-12-02 |
2015-01-10 |
Дайити Санкио Компани, Лимитед |
MODIFIED SINGLE-CHAIN POLYNUCLEOTIDE
|
CN102559666B
(en)
|
2010-12-18 |
2013-12-25 |
中国科学院上海生命科学研究院 |
Plant virus inhibitory artificial miRNA (microRNA) and construction and application thereof
|
BR112013019853A2
(en)
*
|
2011-02-03 |
2017-03-21 |
Mirna Therapeutics Inc |
mir-34 synthetic mimetics
|
CN102784398B
(en)
|
2011-05-16 |
2014-06-18 |
南京大学 |
Composition comprising endostatin adopted as delivery system and chemically-synthesized RNA interference molecule, and application thereof
|
JP6011945B2
(en)
|
2011-05-20 |
2016-10-25 |
公一 中城 |
Composition comprising microRNA or expression system thereof
|
EP2527440A1
(en)
|
2011-05-27 |
2012-11-28 |
Institut Curie |
Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
|
JP2013055913A
(en)
|
2011-09-09 |
2013-03-28 |
Bonac Corp |
Single-stranded rna molecule for gene expression control
|
WO2013077446A1
(en)
|
2011-11-26 |
2013-05-30 |
株式会社ボナック |
Single-stranded nucleic acid molecule for regulating expression of gene
|
CN110055247A
(en)
|
2012-01-07 |
2019-07-26 |
株式会社博纳克 |
Single stranded nucleic acid molecule with amino acid backbone
|
JP2013153736A
(en)
|
2012-01-07 |
2013-08-15 |
Bonac Corp |
Single strand nucleic acid molecule having peptide skeleton
|
WO2013133221A1
(en)
|
2012-03-04 |
2013-09-12 |
株式会社ボナック |
micro-RNA INHIBITOR
|
AR090905A1
(en)
|
2012-05-02 |
2014-12-17 |
Merck Sharp & Dohme |
CONJUGATES CONTAINING TETRAGALNAC AND PEPTIDES AND PROCEDURES FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES, PHARMACEUTICAL COMPOSITION
|
JP6126088B2
(en)
|
2012-05-26 |
2017-05-10 |
株式会社ボナック |
Single-stranded nucleic acid molecule for gene expression control with delivery function
|
CA2942833A1
(en)
|
2013-03-15 |
2014-09-18 |
Ohio State Innovation Foundation |
Inhibitors of prmt5 and methods of their use
|
CN105452463B
(en)
|
2013-05-22 |
2019-06-21 |
阿尔尼拉姆医药品有限公司 |
TMPRSS6 IRNA composition and its application method
|
WO2015093495A1
(en)
|
2013-12-16 |
2015-06-25 |
株式会社ボナック |
Single-stranded nucleic acid molecule for controlling expression of tgf-β1 gene
|
JP6486836B2
(en)
|
2013-12-26 |
2019-03-20 |
学校法人東京医科大学 |
Artificial mimic miRNA for gene expression control and use thereof
|
EP3088525A4
(en)
|
2013-12-27 |
2017-08-09 |
Bonac Corporation |
Artificial match-type mirna for controlling gene expression and use therefor
|
JP6492014B2
(en)
|
2013-12-27 |
2019-03-27 |
株式会社ボナック |
Artificial match-type miRNA for gene expression control and use thereof
|
WO2015161255A1
(en)
|
2014-04-18 |
2015-10-22 |
Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno |
Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy
|
MX2017008587A
(en)
|
2014-12-27 |
2017-10-20 |
Bonac Corp |
NATURALLY OCCURING miRNA FOR CONTROLLING GENE EXPRESSION, AND USE OF SAME.
|
US11142769B2
(en)
|
2015-03-27 |
2021-10-12 |
Bonac Corporation |
Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability
|
CA3009769C
(en)
|
2015-12-29 |
2021-01-12 |
National University Corporation Hokkaido University |
Single-stranded nucleic acid molecule inhibiting expression of prorenin gene or prorenin receptor gene, and use thereof
|